Medtronic (MDT): Path to +11% Upside at the $104 Analyst Target

Key Takeaways

• The central target of $104 represents the arithmetic mean of roughly 30 verified analyst price targets, with individual goals ranging from about $83 to $121.
• From a latest verified price near $94, reaching $104 implies upside of roughly 11%, a modest move for a large-cap medtech name over a typical research horizon.
• The analyst range is unusually wide, reflecting a genuine split between bullish firms pointing to an accelerating growth story and cautious firms concerned about valuation and durability of demand.
• The strongest supports are a fiscal 2027 first-quarter "beat-and-raise," broad-based organic growth, and a new-product pipeline across cardiac ablation and robotics.
• The biggest risks are valuation concerns, questions about the sustainability of cardiac ablation share, execution across segments, and broader macroeconomic pressure on medical-device spending.
• For more detail on Major News, Today's Price Move, the Forecast, and Earnings, explore these dedicated pages for deeper coverage of the ticker.
• Explore Trending AI Robots to see how AI-driven trading strategies are approaching stocks like MDT in changing market conditions.

Analyst Views and the $104 Consensus

Across approximately 30 current analyst price targets, individual objectives cluster in a wide band from roughly $83 on the cautious end to about $121 at the top. The arithmetic mean works out to approximately $104, which is the central target used here. Independent aggregators broadly corroborate this figure: S&P Global data places the average near $104–$105, while MarketBeat's 28-analyst average sits just under $103. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The dispersion matters more than the midpoint. Bullish firms include RBC Capital ($118, Buy), Mizuho ($115, Outperform), Needham ($114, Buy), Bernstein ($112, Outperform), and Leerink Partners ($111, Outperform). More cautious voices such as Piper Sandler ($85, Hold), Goldman Sachs (low $80s, Hold), and Deutsche Bank ($92, Hold) argue that much of the growth story is already reflected in the multiple. Barclays initiated coverage with an Equal Weight rating and a $95 target in early October, framing a neutral stance.

Current Market Position and Path Toward the Target

With the shares near $94, the move to a $104 target requires roughly 11% upside — a modest but not insignificant climb. The path runs through Medtronic's fiscal 2027 first quarter (ended July 31, 2026), which delivered revenue of $9.76 billion and net income of $1.47 billion, up from $8.58 billion and $1.04 billion a year earlier. Reported organic revenue growth of 13.7% was flattered by an extra fiscal week contributing about $570 million, but management still raised full-year organic growth guidance to 7.25%–7.75%.

Cardiac Ablation Solutions was the standout, with revenue up 88%, while cardiac rhythm management, pelvic health, and diabetes each grew about 15%. This broadening beyond a single growth engine is central to the bull case for a higher valuation, though analysts disagree on whether it justifies a re-rating.

What Could Support a Move Toward the Target

• Broadening growth beyond one segment, with cardiovascular and diabetes franchises now contributing alongside cardiac ablation.
• A beat-and-raise quarter that pushed several firms to lift targets in early September.
• A $700 million investment in Cornerstone Robotics, strengthening the Hugo surgical platform.
• A dividend yield around 3.2%, which supports total-return appeal while growth plays out.
• Improving institutional positioning, with short interest falling and several large funds adding positions.

What Could Prevent the Target From Being Reached

• Valuation concerns, with cautious analysts arguing the forward P/E already prices in much of the fiscal 2027 recovery.
• Skepticism about whether cardiac ablation share gains are sustainable into 2027 as competitors respond.
• Execution risk across a broad portfolio, and questions around the durability of the Hugo robotic platform.
• Macroeconomic pressure on hospital capital budgets and elective-procedure volumes.
• Recent insider selling, flagged by some research as a signal worth monitoring.

Technical Levels and Market Structure

The shares have recovered from a July 2026 low near $79 to the mid-$90s, but the $100 round-number level remains an important psychological hurdle sitting between the current price and the $104 target. Many analyst targets cluster in the $100–$118 zone, suggesting that a sustained move above $100 could be the structural step needed before the central target comes into view. A failure to hold recent gains could see the stock retest support near its earlier 2026 lows.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary in their modeling windows. Key items ahead include Medtronic's next quarterly earnings and any update to fiscal 2027 guidance, additional analyst target revisions, commentary on cardiac ablation market share, the integration of the Cornerstone Robotics investment, and broader economic data affecting hospital spending. Management's December Investor Day could also clarify the longer-term growth trajectory.

Using AI Daily Buy/Sell Signals for Monitoring

In my own research process, I often rely on AI Daily Buy/Sell Signals to track how market conditions shift for names like MDT. These AI-driven tools scan thousands of stocks and ETFs daily, producing Buy, Sell, or Hold signals that help highlight potential entry or exit points alongside traditional analysis. They have proven useful for balancing the wide analyst dispersion seen here.

Final Assessment

The $104 central target reflects the average of roughly 30 analyst objectives spanning $83 to $121, and it implies about 11% upside from a price near $94. The bull case rests on a broadening, beat-and-raise growth story and a strengthening pipeline, while the bear case centers on valuation, competitive pressure in cardiac ablation, and execution risk. The wide target range signals genuine disagreement about how much of the recovery is already priced in. Whether Medtronic reaches $104 will depend on sustained organic growth, guidance durability, and whether investors award the stock a higher multiple — none of which is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume